IN202121031414A - - Google Patents

Download PDF

Info

Publication number
IN202121031414A
IN202121031414A IN202121031414A IN202121031414A IN202121031414A IN 202121031414 A IN202121031414 A IN 202121031414A IN 202121031414 A IN202121031414 A IN 202121031414A IN 202121031414 A IN202121031414 A IN 202121031414A IN 202121031414 A IN202121031414 A IN 202121031414A
Authority
IN
India
Application number
IN202121031414A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to IN202121031414A priority Critical patent/IN202121031414A/en
Priority to EP22841629.3A priority patent/EP4351521A4/en
Priority to US18/578,881 priority patent/US20240325522A1/en
Priority to KR1020247004893A priority patent/KR20240035836A/ko
Priority to CA3226213A priority patent/CA3226213A1/en
Priority to PCT/IN2022/050624 priority patent/WO2023286076A1/en
Priority to AU2022310435A priority patent/AU2022310435A1/en
Priority to JP2024501633A priority patent/JP2024525709A/ja
Publication of IN202121031414A publication Critical patent/IN202121031414A/en
Priority to ZA2024/00149A priority patent/ZA202400149B/en
Priority to CONC2024/0000205A priority patent/CO2024000205A2/es
Priority to CL2024000120A priority patent/CL2024000120A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
IN202121031414A 2021-07-13 2021-07-13 IN202121031414A (enExample)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IN202121031414A IN202121031414A (enExample) 2021-07-13 2021-07-13
PCT/IN2022/050624 WO2023286076A1 (en) 2021-07-13 2022-07-08 Rna adsorbed onto lipid nano-emulsion particles and its formulations.
US18/578,881 US20240325522A1 (en) 2021-07-13 2022-07-08 Rna adsorbed onto lipid nano-emulsion particles and its formulations
KR1020247004893A KR20240035836A (ko) 2021-07-13 2022-07-08 지질 나노-에멀젼 입자에 흡착된 rna 및 그 제제
CA3226213A CA3226213A1 (en) 2021-07-13 2022-07-08 Rna adsorbed onto lipid nano-emulsion particles and its formulations.
EP22841629.3A EP4351521A4 (en) 2021-07-13 2022-07-08 RNA ADSORBED ON LIPID NANO-EMULSION PARTICLES AND ITS FORMULATIONS
AU2022310435A AU2022310435A1 (en) 2021-07-13 2022-07-08 Rna adsorbed onto lipid nano-emulsion particles and its formulations.
JP2024501633A JP2024525709A (ja) 2021-07-13 2022-07-08 脂質ナノエマルション粒子に吸着したｒｎａとその製剤
ZA2024/00149A ZA202400149B (en) 2021-07-13 2024-01-03 Rna adsorbed onto lipid nano-emulsion particles and its formulations.
CONC2024/0000205A CO2024000205A2 (es) 2021-07-13 2024-01-12 Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones
CL2024000120A CL2024000120A1 (es) 2021-07-13 2024-01-15 Arn adorbido sobre partículas de nanoemulsión lipídica y sus formulaciones.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202121031414A IN202121031414A (enExample) 2021-07-13 2021-07-13

Publications (1)

Publication Number Publication Date
IN202121031414A true IN202121031414A (enExample) 2023-01-13

Family

ID=84920187

Family Applications (1)

Application Number Title Priority Date Filing Date
IN202121031414A IN202121031414A (enExample) 2021-07-13 2021-07-13

Country Status (11)

Country Link
US (1) US20240325522A1 (enExample)
EP (1) EP4351521A4 (enExample)
JP (1) JP2024525709A (enExample)
KR (1) KR20240035836A (enExample)
AU (1) AU2022310435A1 (enExample)
CA (1) CA3226213A1 (enExample)
CL (1) CL2024000120A1 (enExample)
CO (1) CO2024000205A2 (enExample)
IN (1) IN202121031414A (enExample)
WO (1) WO2023286076A1 (enExample)
ZA (1) ZA202400149B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024261766A1 (en) * 2023-06-23 2024-12-26 Gennova Biopharmaceuticals Ltd. Lyophilised vaccine formulation

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
WO2023048759A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Sars-cov-2 rna vaccine compositions and methods of use
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
EP4404957A4 (en) 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
GB2615177A (en) * 2021-11-29 2023-08-02 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2025006870A1 (en) * 2023-06-29 2025-01-02 Rigimmune Inc. Novel formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012280904B2 (en) * 2011-07-06 2017-02-23 Glaxosmithkline Biologicals S.A. Cationic oil-in-water emulsions
KR20240096685A (ko) * 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024261766A1 (en) * 2023-06-23 2024-12-26 Gennova Biopharmaceuticals Ltd. Lyophilised vaccine formulation

Also Published As

Publication number Publication date
AU2022310435A1 (en) 2024-01-25
CA3226213A1 (en) 2023-01-19
ZA202400149B (en) 2024-08-28
CL2024000120A1 (es) 2024-08-16
JP2024525709A (ja) 2024-07-12
WO2023286076A1 (en) 2023-01-19
EP4351521A4 (en) 2025-12-10
EP4351521A1 (en) 2024-04-17
US20240325522A1 (en) 2024-10-03
CO2024000205A2 (es) 2024-01-25
KR20240035836A (ko) 2024-03-18

Similar Documents

Publication Publication Date Title
CN305527236S (enExample)
CN305836168S (enExample)
CN305529945S (enExample)
CN305538313S (enExample)
CN305540531S (enExample)
CN305541696S (enExample)
CN305562788S (enExample)
CN305621908S (enExample)
CN305668880S (enExample)
CN305669067S (enExample)
CN305669572S (enExample)
CN305670430S (enExample)
CN305680021S (enExample)
CN305680680S (enExample)
CN305684437S (enExample)
CN305686431S (enExample)
CN305687468S (enExample)
CN305688839S (enExample)
CN305735717S (enExample)
CN305737696S (enExample)
CN305747422S (enExample)
CN305766035S (enExample)
CN305767585S (enExample)
CN305768687S (enExample)
CN305770124S (enExample)